Compare Enveric Biosciences Inc (ENVB) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lockheed Martin Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Lockheed Martin Corporation trades at $508.37 (market cap $115.22B). The key difference: Lockheed Martin Corporation is far larger — about 17222.7× Enveric Biosciences Inc's market cap, and Lockheed Martin Corporation pays a 2.76% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Lockheed Martin Corporation for 86 Days on average.
| ENVB | LMT | |
|---|---|---|
Market Cap | $6.69M | $115.22B |
Volume | 41,141 | 1,073,075 |
Sector | Health | Industrials |
52-Week High | $10.80 | $676.70 |
52-Week Low | $1.27 | $439.19 |
Typical Hold Time | 14 Days | 86 Days |
Enterprise Value | -$1.60M | $131.96B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Lockheed Martin (LMT) trades at $507.89, down 0.44% on the day, with a bearish technical signal driven by moving averages. The stock shows strong profitability with an 8.16% net margin and 89.16% ROE, but recent earnings missed expectations in two of the last three quarters. Revenue growth is steady, projected to reach $77B in 2026, while analyst sentiment remains positive with a $645.50 consensus price target. Recent news highlights dividend increases and AI integration initiatives.
The outlook for LMT is supported by robust defense spending and a high analyst buy rating (59%), but risks include fixed-price contract volatility and debt levels. The stock offers a dividend yield near 0.7% with 23 consecutive years of increases. Upside potential exists if earnings rebound, though technical resistance near $510 may cap near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
